Titlebook: Brain Protection in Schizophrenia, Mood and Cognitive Disorders; Michael S. Ritsner Book 2010 Springer Science+Business Media B.V. 2010 Co

譏諷

refine

One-Compound-Multi-Targets at Amyloid β Cascade Offered By Bis(7)-Cognitin, a Novel Anti-Alzheimer’sgical hallmarks of AD are senile plaques, which are extracellular deposits predominantly composed of fibrillar amyloid β peptide (Aβ), and intracellular neurofibrillary tangles composed of filamentous aggregates called paired helical filaments of hyperphosphorylated tau protein. Aβ is proposed to pl

Freeze

改良

GRAIN

魅力

cumulative

Is a Neuroprotective Therapy Suitable for Schizophrenia Patients?ed distress and a significant decline in cognition, quality of life and psychosocial functioning. About one-third of all patients with schizophrenia do not respond adequately to drug treatment. Today neuroscience and clinical research have sufficiently advanced to introduce a novel generation of com

終點(diǎn)

懶鬼才會衰弱

Neuroprotective Agents in Mood Disorders: Pathophysiological and Therapeutic Implicationse last decade due to our expanding knowledge of the pathophysiology and treatment of these illnesses. While previous research focused exclusively on abnormalities of the monoaminergic neurotransmitter systems, more recent preclinical and clinical studies have emphasized the role of impaired neuropla

glacial